701977-09-5

Basic information

• Product Name: N-[(1S,2S)-3-(4-Chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[(5-(trifluoromethyl)pyridin-2-yl)oxy]propanamide( MK 0364)
• Synonyms: N-[(1S,2S)-3-(4-Chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[(5-(trifluoromethyl)pyridin-2-yl)oxy]propanamide( MK 0364);MK 0364;N-[(1S,2S)-3-(4-Chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[(5-(trifluoromethyl)pyridin-2-yl)oxy]propanamide;Taranabant;Tranabant;N-(3-(4-Chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl)-2-methyl-2-((5-(trifluoromethyl)pyridin-2-yl)oxy)propanamide;Propanamide, N-((1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl)-2-methyl-2-((5-(trifluoromethyl)-2-pyridinyl)oxy)-;Taranabant [usan]
• CAS NO: 701977-09-5
• Molecular Formula: C₂₇H₂₅ClF₃N₃O₂
• Molecular Weight: 515.95
• Mol File: 701977-09-5.mol
• Article Data: 10

Chemical Properties

• Melting Point: 106.0-106.3 °C
• Boiling Point: 634.2 °C at 760 mmHg
• Flash Point: 337.4 °C
• Appearance: /
• Density: 1.30
• PKA: 14.55±0.46(Predicted)
• CAS DataBase Reference: N-[(1S,2S)-3-(4-Chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[(5-(trifluoromethyl)pyridin-2-yl)oxy]propanamide( MK 0364)(CAS DataBase Reference)
• NIST Chemistry Reference: N-[(1S,2S)-3-(4-Chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[(5-(trifluoromethyl)pyridin-2-yl)oxy]propanamide( MK 0364)(701977-09-5)
• EPA Substance Registry System: N-[(1S,2S)-3-(4-Chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[(5-(trifluoromethyl)pyridin-2-yl)oxy]propanamide( MK 0364)(701977-09-5)

Safety Data

• Hazardous Substances Data: 701977-09-5(Hazardous Substances Data)

Usage

General Description

MK 0364 is a chemical compound with the molecular formula C28H24ClF3N4O2. It is also known as N-[(1S,2S)-3-(4-Chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[(5-(trifluoromethyl)pyridin-2-yl)oxy]propanamide. MK 0364 is a potent and selective potassium channel opener, and it has shown potential for the treatment of various conditions, including epilepsy and neuropathic pain. It works by modulating the activity of certain potassium channels in the brain and nervous system, which can help to reduce abnormal electrical activity and alleviate symptoms associated with these conditions. Additionally, MK 0364 has been studied for its potential use in treating anxiety and depression. Its complex chemical structure and specific mode of action make it a promising candidate for further research and development in the field of neuroscience and drug discovery.

InChI:InChI=1/C27H25ClF3N3O2/c1-17(34-25(35)26(2,3)36-24-12-9-21(16-33-24)27(29,30)31)23(14-18-7-10-22(28)11-8-18)20-6-4-5-19(13-20)15-32/h4-13,16-17,23H,14H2,1-3H3,(H,34,35)

Upstream product

• 605680-62-4 2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanoic acid 
• 610791-48-5 N-[3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]amine hydrochloride 
• 848310-98-5 3-(3-bromophenyl)-4-(4-chlorophenyl)butan-2-one 
• 913849-17-9 ethyl 2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanoate 
• 33252-63-0 2-hydroxy-5-(trifluoromethyl)pyridine 
• 622-95-7 4-chlorobenzyl bromide 
• 150529-73-0 methyl 2-(3-bromophenyl)acetatee 
• 732982-66-0 N-(1S,2S)-[2-(3-cyanophenyl)-3-(4-chlorophenyl)-1-methylpropyl]amine 
• 876365-72-9 3-{(1S,2S)-1-(4-chlorobenzyl)-2-[(2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanoyl)amino]propyl}benzamide 
• 876365-70-7 N-[(1Z)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylprop-1-en-1-yl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide 
• 1878-67-7 3-Bromophenylacetic acid 
• 1204241-05-3 C₁₅H₁₁BrCl₂O 
• 941280-51-9 2-(3-bromophenyl)-3-(4-chlorophenyl)propionic acid 

Relevant articles and documents

New efficient asymmetric synthesis of taranabant, a CB1R inverse agonist for the treatment of obesity

Taranabant (1) is a cannabinoid-1 receptor (CB1R) inverse agonist that was recently in late-stage clinical development for the treatment of obesity. The previously employed synthesis exhibited a number of shortcomings for continuing development, and in th

Catalytic, enantioselective synthesis of taranabant, a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity

Chiral amide 1 (MK-0364, taranabant) is a potent, selective, and orally bioavailable cannabinoid-1 receptor (CB-1R) inverse agonist indicated for the treatment of obesity. An asymmetric synthesis featuring a dynamic kinetic resolution via hydrogenation fo

COMBINATION OF DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND A CANNABINOID CB1 RECEPTOR ANTAGONIST FOR THE TREATMENT OF DIABETES AND OBESITY

The present invention relates to pharmaceutical compositions comprising a combination of a particular dipeptidyl peptidase-IV (DPP-IV) inhibitor and a particular cannabinoid CB?1#191 receptor antagonist/inverse agonist, kits containing such combinations and methods of using such compositions for the treatment of diabetes, diabetes associated with obesity, diabetes-related disorders, obesity, and obesity-related disorders.